[肺恶性上腔静脉阻塞：血管内支架治疗]
[Pulmonary malignant superior vena cava obstruction: endovascular stent therapy].
作者信息
Berna P, Bagan P, Renard C, Auquier M, Remond A, Riquet M
机构信息
Service de chirurgie thoracique et vasculaire, CHU d'Amiens-Sud, avenue René-Laënnec-Salouel, 80054 Amiens cedex 1, France.
出版信息
Rev Pneumol Clin. 2008 Jun;64(3):129-32. doi: 10.1016/j.pneumo.2008.04.009. Epub 2008 Jul 3.
MATERIALS AND METHODS
Thirty-one patients underwent stent placement between June 1998 and October 2006 for superior vena cava obstruction. The initial effectiveness of the metallic stent therapy and the follow-up results were studied at one, six and 12 months.
PURPOSE
We retrospectively studied the utility of metallic stent placement for the treatment of malignant superior vena cava obstruction in 31 patients (SVCO) on the basis of long-term follow-up data.
RESULTS
The initial clinical success rate was 100% (31 out of 31), the primary clinical patency rate was 93% (26 out of 28) at six months. The obstruction rate of the stent was 7% (two out of 28) at six months. There was no additional stent used for recurrence. At 12 months, 27 out of 31 patients were deceased in whom there was no recurrence of SVCO until death.
CONCLUSION
Stent therapy is an effective treatment for SVCO. Adjuvant therapy must to be evaluated in association with stent therapy.
材料与方法
1998年6月至2006年10月期间，31例患者因上腔静脉阻塞接受了支架置入术。在1个月、6个月和12个月时研究了金属支架治疗的初始效果及随访结果。
目的
我们基于长期随访数据，回顾性研究了31例恶性上腔静脉阻塞（SVCO）患者中金属支架置入术的效用。
结果
初始临床成功率为100%（31例中的31例），6个月时主要临床通畅率为93%（28例中的26例）。6个月时支架阻塞率为7%（28例中的2例）。没有为复发而使用额外的支架。12个月时，31例患者中有27例死亡，直至死亡时SVCO均未复发。
结论
支架治疗是SVCO的有效治疗方法。必须结合支架治疗评估辅助治疗。
Zotero 插件